A taxonomy of model structures for economic evaluation of health technologies

被引:319
作者
Brennan, Alan
Chick, Stephen E.
Davies, Ruth
机构
[1] Univ Sheffield, Sch Hlth & Related Res, Sheffield S14 DA, S Yorkshire, England
[2] INSEAD, Technol & Operat Management Area, Hlth Management Inst, Fontainebleau, France
[3] Univ Warwick, Warwick Business Sch, Coventry, W Midlands, England
关键词
health technology assessment; cost-effectiveness analysis; modelling methodology; simulation; decision tree; Markov model;
D O I
10.1002/hec.1148
中图分类号
F [经济];
学科分类号
02 ;
摘要
Models for the economic evaluation of health technologies provide valuable information to decision makers. The choice of model structure is rarely discussed in published studies and can affect the results produced. Many papers describe good modelling practice, but few describe how to choose from the many types of available models. This paper develops a new taxonomy of model structures. The horizontal axis of the taxonomy describes assumptions about the role of expected values, randomness, the heterogeneity of entities, and the degree of non-Markovian structure. Commonly used aggregate models, including decision trees and Markov models require large population numbers, homogeneous sub-groups and linear interactions. Individual models are more flexible, but may require replications with different random numbers to estimate expected values. The vertical axis of the taxonomy describes potential interactions between the individual actors, as well as how the interactions occur through time. Models using interactions, such as system dynamics, some Markov models, and discrete event simulation are fairly uncommon in the health economics but are necessary for modelling infectious diseases and systems with constrained resources. The paper provides guidance for choosing a model, based on key requirements, including output requirements, the population size, and system complexity. Copyright (c) 2006 John Wiley & Sons, Ltd.
引用
收藏
页码:1295 / 1310
页数:16
相关论文
共 65 条
  • [1] Simulations to evaluate HIV vaccine trial designs
    Adams, AL
    Barth-Jones, DC
    Chick, SE
    Koopman, JS
    [J]. SIMULATION, 1998, 71 (04) : 228 - 241
  • [2] Bayesian methods for evidence synthesis in cost-effectiveness analysis
    Ades, AE
    Sculpher, M
    Sutton, A
    Abrams, K
    Cooper, N
    Welton, N
    Lu, GB
    [J]. PHARMACOECONOMICS, 2006, 24 (01) : 1 - 19
  • [3] BABAD H, 2002, HLTH CARE MANAGE SCI, V2, P69
  • [4] BANKS J, 1995, DISCRETE EVENT SYSTE
  • [5] BANKS J, 1996, HDB SIMULATION
  • [6] Barton P, 2004, HEALTH TECHNOL ASSES, V8, P1
  • [7] Barton Pelham, 2004, J Health Serv Res Policy, V9, P110, DOI 10.1258/135581904322987535
  • [8] Assessing the risk of vCJD transmission via surgery: models for uncertainty and complexity
    Bennett, P
    Hare, A
    Townshend, J
    [J]. JOURNAL OF THE OPERATIONAL RESEARCH SOCIETY, 2005, 56 (02) : 202 - 213
  • [9] Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK
    Brennan, A
    Bansback, N
    Reynolds, A
    Conway, P
    [J]. RHEUMATOLOGY, 2004, 43 (01) : 62 - 72
  • [10] An introduction to Markov modelling for economic evaluation
    Briggs, A
    Sculpher, M
    [J]. PHARMACOECONOMICS, 1998, 13 (04) : 397 - 409